谷胱甘肽/肌苷(Glutathione/Inosine) - 药物靶点：NGFB_在研适应症：乙型肝炎，丙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Molixan

靶点

NGFB

作用方式

刺激剂

作用机制

NGFB刺激剂(β-神经生长因子刺激剂)

治疗领域

感染消化系统疾病

在研适应症

乙型肝炎丙型肝炎

非在研适应症

新型冠状病毒感染慢性丙型肝炎辐射损伤

原研机构

Cellectar Biosciences, Inc.

在研机构

Sleep Number Labs

非在研机构

Cellectar Biosciences, Inc.

权益机构-

最高研发阶段批准上市

首次获批日期

俄罗斯 (2006-09-10),

丙型肝炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H12N4O5

InChIKeyUGQMRVRMYYASKQ-KQYNXXCUSA-N

CAS号58-63-9

查看全部结构式(2)

关联

3

项与谷胱甘肽/肌苷相关的临床试验

NCT04780672

/ Unknown status临床3期IIT

Clinical Study to Analyze the Safety and Efficacy of Molixan® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19)

Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.
The study is designed for 2 treatment groups:
Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug.
Group 2 of comparison - Patients receive standard therapy and placebo.

开始日期2021-03-09

申办/合作机构

Pharma VAM

NCT01058512

/ Completed临床2期

A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.

开始日期2010-03-01

申办/合作机构

Cellectar Biosciences, Inc.

NCT00372983

/ Completed临床1期

A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C. In addition, this trial will test how NOV-205 is absorbed by your body after single and multiple doses of the trial drug, and it will look for early signs of therapeutic activity (decreases in indicators in the blood for the hepatitis C virus and for liver damage). This is known as pharmacokinetics (PK). NOV-205 is an experimental drug. "Experimental" means that the trial drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA). However, NOV-205 has been approved by the Russian Federation for treatment of liver diseases including hepatitis C. Clinical studies in that country showed that subjects treated with NOV-205 alone had decreased indicators in the blood for the hepatitis C virus and for liver damage.

开始日期2006-08-01

申办/合作机构

Cellectar Biosciences, Inc.

100 项与谷胱甘肽/肌苷相关的临床结果

登录后查看更多信息

100 项与谷胱甘肽/肌苷相关的转化医学

登录后查看更多信息

100 项与谷胱甘肽/肌苷相关的专利（医药）

登录后查看更多信息

18

项与谷胱甘肽/肌苷相关的文献（医药）

2022-06-01·Cell and Tissue Biology

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca2+ Responses in Rat Peritoneal Macrophages

Article

作者: Antonov, V G ; Milenina, L S ; Krutetskaya, Z I ; Krutetskaya, N I

Sigma-1 receptors are ubiquitous multifunctional ligand-regulated molecular chaperones in the endoplasmic reticulum membrane with a unique history, structure, and pharmacological profile. Sigma-1 receptors bind ligands of different chemical structure and pharmacological action and modulate a wide range of cellular processes in health and disease, including Ca²⁺ signaling. To elucidate the involvement of sigma-1 receptors in the processes of Ca²⁺ signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca²⁺ responses induced by inhibitors of endoplasmic Ca²⁺-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. Using Fura-2AM microfluorimetry we showed for the first time that chlorpromazine and trifluoperazine inhibit both phases of Ca²⁺ responses induced by Glutoxim, Molixan, thapsigargin, and cyclopiazonic acid in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca²⁺ concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Ca²⁺entry in macrophages.

2020-01-01·Doklady Biochemistry and Biophysics4区 · 生物学

Neuroleptic Chlorpromazine Modulates Ca2+ Responses in Macrophages

4区 · 生物学

Article

作者: Nozdrachev, A D ; Krutetskaya, Z I ; Milenina, L S ; Antonov, V G

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca²⁺ responses and Ca²⁺ responses induced by endoplasmic reticulum Са²⁺-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase and in the regulation of store-dependent Ca²⁺ entry in macrophages.

2018-07-01·Doklady Biochemistry and Biophysics

Amitriptyline Attenuates Ca2+ Responses Induced by Glutoxim and Molixan in Macrophages

Article

作者: Antonov, V G ; Naumova, A A ; Krutetskaya, Z I ; Milenina, L S ; Nozdrachev, A D ; Butov, S N

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor agonist, tricyclic antidepressant amitriptyline, significantly inhibits glutoxim- and molixan-induced Ca²⁺-responses in rat peritoneal macrophages. The results suggest possible involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase in macrophages.

100 项与谷胱甘肽/肌苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A05A	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
乙型肝炎	俄罗斯	Sleep Number Labs	2006-10-27
丙型肝炎	俄罗斯	Sleep Number Labs	2006-09-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
辐射损伤	临床3期	美国	Cellectar Biosciences, Inc.	-
新型冠状病毒感染	临床前	俄罗斯	Sleep Number Labs	2021-03-06
慢性丙型肝炎	临床前	美国	Cellectar Biosciences, Inc.	2010-03-01